{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=naltrexone+%28Revia%29&page=2",
    "query": {
      "intervention": "naltrexone (Revia)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 415,
    "total_pages": 42,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=naltrexone+%28Revia%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=naltrexone+%28Revia%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T03:16:20.101Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00149669",
      "title": "Employment-based Reinforcement of Naltrexone Ingestion and Abstinence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cocaine-Related Disorders",
        "Heroin Dependence",
        "Opioid-Related Disorders",
        "Substance Abuse, Intravenous"
      ],
      "interventions": [
        {
          "name": "employment-based reinforcement",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 67,
      "start_date": "2005-12",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2017-09-14",
      "last_synced_at": "2026-09-30T03:16:20.101Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00149669"
    },
    {
      "nct_id": "NCT02437344",
      "title": "Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid Dependence"
      ],
      "interventions": [
        {
          "name": "CI-581aa",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone titration and XR-NTX initiation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 16,
      "start_date": "2015-01",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2019-04-08",
      "last_synced_at": "2026-09-30T03:16:20.101Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02437344"
    },
    {
      "nct_id": "NCT01822132",
      "title": "Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Methamphetamine Abuse",
        "HIV"
      ],
      "interventions": [
        {
          "name": "Extended release naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 76,
      "start_date": "2013-05",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-09-30T03:16:20.101Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01822132"
    },
    {
      "nct_id": "NCT04322526",
      "title": "Study of Naltrexone-Induced Blockade of Antidepressant Effects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression",
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Naltrexone 50 Mg Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marta Peciña, MD PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 25,
      "start_date": "2017-07-01",
      "completion_date": "2018-07-15",
      "has_results": true,
      "last_update_posted_date": "2020-04-21",
      "last_synced_at": "2026-09-30T03:16:20.101Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04322526"
    },
    {
      "nct_id": "NCT01723384",
      "title": "Intermittent Naltrexone Among Polysubstance Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Methamphetamine",
        "Alcohol"
      ],
      "interventions": [
        {
          "name": "Intermittent Oral Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "18 Years to 70 Years · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2013-05",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2019-04-23",
      "last_synced_at": "2026-09-30T03:16:20.101Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01723384"
    },
    {
      "nct_id": "NCT01739192",
      "title": "A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cocaine Use Disorders"
      ],
      "interventions": [
        {
          "name": "Bupropion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Craig Rush",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 34,
      "start_date": "2013-01",
      "completion_date": "2018-06",
      "has_results": false,
      "last_update_posted_date": "2018-06-26",
      "last_synced_at": "2026-09-30T03:16:20.101Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01739192"
    },
    {
      "nct_id": "NCT00000449",
      "title": "Behavior and Naltrexone Treatment for Alcoholics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alcoholism"
      ],
      "interventions": [
        {
          "name": "naltrexone (Revia)",
          "type": "DRUG"
        },
        {
          "name": "cognitive behavioral therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "cue exposure treatment",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 160,
      "start_date": null,
      "completion_date": "2000-03",
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-09-30T03:16:20.101Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000449"
    },
    {
      "nct_id": "NCT01024335",
      "title": "Dronabinol Naltrexone Treatment for Opioid Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Opioid Dependence"
      ],
      "interventions": [
        {
          "name": "injectable naltrexone and dronabinol",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone and placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2010-01",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2018-06-18",
      "last_synced_at": "2026-09-30T03:16:20.101Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01024335"
    },
    {
      "nct_id": "NCT00474630",
      "title": "A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity",
        "Overweight",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Naltrexone SR 32 mg/bupropion SR 360 mg/ day",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ancillary therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Orexigen Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 505,
      "start_date": "2007-05",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2014-11-21",
      "last_synced_at": "2026-09-30T03:16:20.101Z",
      "location_count": 53,
      "location_summary": "Fairhope, Alabama • Peoria, Arizona • Phoenix, Arizona + 46 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00474630"
    },
    {
      "nct_id": "NCT01015066",
      "title": "Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Opiate Addiction"
      ],
      "interventions": [
        {
          "name": "Buprenorphine/naloxone",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "16 Years to 25 Years"
      },
      "enrollment_count": 0,
      "start_date": "2009-11",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-06-10",
      "last_synced_at": "2026-09-30T03:16:20.101Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01015066"
    }
  ]
}